PE20120576A1 - Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion farmaceuticamente aceptable - Google Patents

Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion farmaceuticamente aceptable

Info

Publication number
PE20120576A1
PE20120576A1 PE2011000106A PE2011000106A PE20120576A1 PE 20120576 A1 PE20120576 A1 PE 20120576A1 PE 2011000106 A PE2011000106 A PE 2011000106A PE 2011000106 A PE2011000106 A PE 2011000106A PE 20120576 A1 PE20120576 A1 PE 20120576A1
Authority
PE
Peru
Prior art keywords
ivabradine
pharmaceutically acceptable
substituted
addition salts
acceptable addition
Prior art date
Application number
PE2011000106A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Louis Peglion
Pascal Caignard
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20120576A1 publication Critical patent/PE20120576A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/06One of the condensed rings being a six-membered aromatic ring the other ring being four-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2011000106A 2010-02-17 2011-01-31 Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion farmaceuticamente aceptable PE20120576A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1000657A FR2956401B1 (fr) 2010-02-17 2010-02-17 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (1)

Publication Number Publication Date
PE20120576A1 true PE20120576A1 (es) 2012-05-12

Family

ID=42133409

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000106A PE20120576A1 (es) 2010-02-17 2011-01-31 Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion farmaceuticamente aceptable

Country Status (36)

Country Link
US (1) US8278440B2 (el)
EP (1) EP2364972B1 (el)
JP (1) JP5306387B2 (el)
KR (1) KR101310683B1 (el)
CN (3) CN103265491B (el)
AR (1) AR080178A1 (el)
AU (1) AU2011200403B2 (el)
BR (1) BRPI1100169A2 (el)
CA (1) CA2731315C (el)
CL (1) CL2011000297A1 (el)
CY (1) CY1113338T1 (el)
DK (1) DK2364972T3 (el)
EA (1) EA019373B1 (el)
ES (1) ES2396042T3 (el)
FR (1) FR2956401B1 (el)
GE (1) GEP20135737B (el)
HK (3) HK1162021A1 (el)
HR (1) HRP20120955T1 (el)
JO (1) JO2854B1 (el)
MA (1) MA32681B1 (el)
ME (1) ME01464B (el)
MX (1) MX2011001465A (el)
MY (1) MY147697A (el)
NZ (1) NZ590883A (el)
PE (1) PE20120576A1 (el)
PL (1) PL2364972T3 (el)
PT (1) PT2364972E (el)
RS (1) RS52529B (el)
SA (1) SA111320199B1 (el)
SG (1) SG173961A1 (el)
SI (1) SI2364972T1 (el)
TW (1) TWI395738B (el)
UA (1) UA106208C2 (el)
UY (1) UY33211A (el)
WO (1) WO2011101558A1 (el)
ZA (1) ZA201100964B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2950343B1 (fr) * 2009-09-18 2011-11-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN102566619B (zh) * 2012-02-07 2013-12-25 宁波市镇海华泰电器厂 噪声式水温控制装置
FR2988720B1 (fr) 2012-03-27 2014-03-14 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
AU2003239508A1 (en) * 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
TW200817334A (en) * 2005-02-07 2008-04-16 Servier Lab New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ATE544754T1 (de) * 2006-11-30 2012-02-15 Cadila Healthcare Ltd Verfahren zur herstellung von ivabradinhydrochlorid
CN101284813B (zh) * 2007-04-12 2012-08-15 上海优拓医药科技有限公司 伊伐布雷定的制备方法
WO2008146308A2 (en) * 2007-05-30 2008-12-04 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
CN101544605A (zh) * 2008-03-24 2009-09-30 北京深蓝海生物医药科技有限公司 伊伐布雷定及其药学上可接受的加成盐的制备方法
FR2932800B1 (fr) 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
ES2402765T3 (es) 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina

Also Published As

Publication number Publication date
EA201100230A1 (ru) 2011-08-30
JP5306387B2 (ja) 2013-10-02
CL2011000297A1 (es) 2012-02-17
ZA201100964B (en) 2011-10-26
TWI395738B (zh) 2013-05-11
CA2731315C (fr) 2013-03-26
MX2011001465A (es) 2011-08-30
AU2011200403A1 (en) 2011-09-01
UA106208C2 (ru) 2014-08-11
SI2364972T1 (sl) 2012-12-31
GEP20135737B (en) 2013-01-25
JO2854B1 (en) 2015-03-15
EP2364972A1 (fr) 2011-09-14
ME01464B (me) 2014-04-20
RS52529B (en) 2013-04-30
AU2011200403B2 (en) 2015-02-19
AR080178A1 (es) 2012-03-21
CN103232360B (zh) 2014-05-21
TW201144287A (en) 2011-12-16
US8278440B2 (en) 2012-10-02
KR101310683B1 (ko) 2013-09-24
MA32681B1 (fr) 2011-10-02
WO2011101558A1 (fr) 2011-08-25
SA111320199B1 (ar) 2014-05-21
SG173961A1 (en) 2011-09-29
CN103232360A (zh) 2013-08-07
BRPI1100169A2 (pt) 2012-07-31
HRP20120955T1 (hr) 2012-12-31
MY147697A (en) 2013-01-07
NZ590883A (en) 2012-01-12
CY1113338T1 (el) 2016-06-22
CN102161642B (zh) 2014-03-19
DK2364972T3 (da) 2013-01-07
PT2364972E (pt) 2012-10-02
CA2731315A1 (fr) 2011-08-17
CN103265491A (zh) 2013-08-28
CN103265491B (zh) 2015-01-21
ES2396042T3 (es) 2013-02-18
FR2956401A1 (fr) 2011-08-19
UY33211A (el) 2011-07-29
FR2956401B1 (fr) 2012-02-03
JP2011168590A (ja) 2011-09-01
US20110201805A1 (en) 2011-08-18
HK1183295A1 (en) 2013-12-20
PL2364972T3 (pl) 2013-01-31
HK1183488A1 (en) 2013-12-27
EP2364972B1 (fr) 2012-09-19
HK1162021A1 (en) 2012-08-17
EA019373B1 (ru) 2014-03-31
KR20110095210A (ko) 2011-08-24
CN102161642A (zh) 2011-08-24

Similar Documents

Publication Publication Date Title
AR116907A2 (es) Derivado de diazabiciclooctano ópticamente activo y proceso para su preparación
ES2495815T3 (es) Proceso para la síntesis de lacosamida
UY32490A (es) Inhibidores de beta-secretasa
AR092278A1 (es) Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
CO6430460A2 (es) Compuestos tetraciclicos
PE20150224A1 (es) Inhibidores del nampt
BR112014029551A2 (pt) compostos de ácido dimetil-benzoico
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
PE20100487A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина
PE20120576A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion farmaceuticamente aceptable
CL2010000253A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable; y uno de los compuestos intermediarios considerados.
AR088358A1 (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos
CR20130476A (es) Derivados de pirazolidin-3-ona
EA200900943A1 (ru) Новый способ синтеза агомелатина
CL2012000270A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion por formacion del anillo benzoacepino; y los compuestos intermediarios considerados en el procedimiento.
BR112013015532B1 (pt) ácido 2-(alcóxi ou ariloxicarbonil)-4-metil-6-(2,6,6-trimetilcicloex-1-enil)-hex-2-enoico, metódo para sua preparação e seus usos
AR070737A1 (es) Proceso para la elaboracion de (fenilsulfanilfenil) piperidinas
PE20131097A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable

Legal Events

Date Code Title Description
FG Grant, registration